New Drug Application Filing for Ibrutinib Acce... - CLL Support

CLL Support

22,366 members38,466 posts

New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA

Cllcanada profile image
CllcanadaTop Poster CURE Hero
0 Replies

This is NOT an approval, it is the beginning of the approval process but only for two uses or indications... previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

online.wsj.com/article/PR-C...

Another step forward in the approval process...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Diptheria Immunotoxin Effectively Targets B-Cell Malignancies - Phase 1 trial of DT2219

patients with previously treated pre-B acute lymphoblastic leukemia, chronic lymphocytic leukemia,...

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL

Chronic Lymphocytic Leukaemia (CLL) is associated with immune suppression and susceptibility to...

Ibrutinib Slow but steady foreward movement.

relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or...

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

patients with CLL or SLL treated with a previous covalent BTK inhibitor (median previous lines of...

FDA Frontline Approval of Venetoclax and Obinituzumab in the USA

-with-previously-untreated-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll/ This...